Immunosuppressive and tumour-suppressive bone marrow factor
AssigneeLondon Health Sciences Centre
InventorSharwan K. Singhal
Life of this patent
Estimating the term…
Abstract
A novel immunosuppressive factor derived from mammalian bone marrow factor is described, which inhibits T lymphocyte activation and TNF-α production by activated macrophages and also inhibits tumor and leukemia cell growth. The factor provides a novel therapeutic composition for treatment of tumors and of disorders associated with inflammatory reactions or T lymphocyte activation.
Claims34
A purified, water soluble immunosuppressive factor characterised by a molecular weight less than 1000 daltons and movement as a single peak on reverse phase high performance liquid chromatography.
A method for preparing a purified immunosuppressive factor comprising the steps of
- (a) culturing mammalian bone marrow cells to produce a factor-containing supernatant;
- (b) subjecting the supernatant to solid phase extraction to produce a product;
- (c) subjecting the product from step (b) to gel filtration to produce a product;
- (d) subjecting the product from step (c) to anion exchange fast phase liquid chromatography to produce a product;
- (e) subjecting the product from step (d) to amino-high performance liquid chromatography to produce a product;
- and
- (f) subjecting the product from step (e) to reverse phase high performance liquid chromatography to product purified immunosuppressive factor.
Dependencies are inferred from the claim text.